title: A randomized, double-blind comparison of atomoxetine and placebo on response inhibition and interference control in children and adolescents with autism spectrum disorder and comorbid attention-deficit/hyperactivity disorder symptoms.
authors.affiliation: Department of Cognitive Neuroscience, Donders Institute for Brain Cognition and Behavior, Radboud University Nijmegen Medical Center and Karakter Child and Adolescent Psychiatry, University Center Nijmegen, Nijmegen, the Netherlands J.vanderMeer@psy.umcn.nl Department of Psychiatry University Medical Center Groningen University of Groningen Groningen, the Netherlands Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands Karakter Child and Adolescent Psychiatry, University Center Nijmegen, Nijmegen, the Netherlands Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands Karakter Child and Adolescent Psychiatry, University Center Nijmegen, Nijmegen, the Netherlands Department of Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands Department of Clinical Child and Adolescent Studies, Leiden Institute for Brain and Cognition, Faculty of Social Sciences, University of Leiden, Leiden, the Netherlands Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen Medical Center and Karakter Child and Adolescent Psychiatry, University Center Nijmegen, Nijmegen, the Netherlands Karakter Child and Adolescent Psychiatry University Center Nijmegen and Department of Psychiatry Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands Karakter Child and Adolescent Psychiatry, University Center Nijmegen and Department of Psychiatry, Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands.
authors.forename: Jolanda M J
authors.initials: JM
authors.lastname: van der Meer
authors.forename: Myriam
authors.initials: M
authors.lastname: Harfterkamp
authors.forename: Gigi
authors.initials: G
authors.lastname: van de Loo-Neus
authors.forename: Monika
authors.initials: M
authors.lastname: Althaus
authors.forename: Saskia W
authors.initials: SW
authors.lastname: de Ruiter
authors.forename: A Rogier T
authors.initials: AR
authors.lastname: Donders
authors.forename: Leo M J
authors.initials: LM
authors.lastname: de Sonneville
authors.forename: Jan K
authors.initials: JK
authors.lastname: Buitelaar
authors.forename: Pieter J
authors.initials: PJ
authors.lastname: Hoekstra
authors.forename: Nanda N J
authors.initials: NN
authors.lastname: Rommelse
mesh_terms: D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D011437:Propylamines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018759:Adrenergic Uptake Inhibitors; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride